The Manila Times1h
Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in ...
Frontiers19d
Pharmacophore screening, molecular docking, and MD simulations for identification of VEGFR-2 and c-Met potential dual inhibitors
Introduction: The vascular endothelial growth factor receptor 2 (VEGFR-2) and the mesenchymal-epithelial transition factor (c-Met) are critical in the pathogenesis and progression of various cancers ...
Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with ...
Medical Device Network1mon
FDA fast tracks Bracco’s BR55 for Crohn’s disease bowel inflammation detection
Engineered to specifically act on the vascular endothelial growth factor receptor 2 (VEGFR2), BR55 (perfluorobutane/nitrogen lipopeptide-coated microbubbles) injection claims to improve the ultrasound ...
eLife5y
CCN1 interlinks integrin and hippo pathway to autoregulate tip cell activity
Tip cells have a specific molecular signature, characterised by the expression of vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR3, and DLL4. It has been reported that the VEGF gradient ...
eLife8y
VEGFR-2 conformational switch in response to ligand binding
All truncated VEGFR-2 plasmid constructs were engineered in the pcDNA 3.1(+) vector. All the plasmids contained the N-terminal VEGFR2 signal sequence, which is cleaved off during processing. All ...